Artificial intelligence (AI) is transforming how scientific hypotheses are formulated, tested, and applied. Nucleic acid therapeutics can benefit from emerging opportunities but will also face new challenges. AI lowers the barrier to hypothesis generation, increasing the emphasis on critical evaluation, rigorous experimental testing, and expert judgement. The goal of this perspective is to begin that discussion, with an emphasis on basic and applied research at the interface of nucleic acid science and medicine.
No takes yet. Share an insight, caveat, or question.
David R. Corey (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: